Mitomycin c

Phase 3Small molecule

GGynecologic Oncology Group

Mitomycin c is one of 298 small molecule programs targeting Toxicity. It is currently in Phase 3.

Indications

119

Total Trials

Active Trials

297

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

GlaucomaCompleted

Bladder CancerRecruiting

TreatmentRecruiting

Peritoneal CarcinomatosisCompleted

Solid Tumor CancerRecruiting

Efficacy and SafetyRecruiting

EffectivenessRecruiting

Urothelial CarcinomaCompleted

ToxicityPhase 3

Active, not recruiting

GlaucomaPhase 3

Completed

Bladder CancerPhase 3

Recruiting

TreatmentPhase 3

Recruiting

Peritoneal CarcinomatosisPhase 2

Completed

Solid Tumor CancerPhase 2

Recruiting

Efficacy and SafetyPhase 3

Recruiting

EffectivenessPhase 2

Recruiting

Urothelial CarcinomaPhase 2

Completed

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Mitomycin c

GGynecologic Oncology Group

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Niclocide

Bayer

Preclinical

1 4

Minipress

Pfizer

Preclinical

1 5

Alfenta

Jazz Pharmaceuticals

Preclinical

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Intuniv

PPromius Pharma, LLC

Preclinical

1 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Glaucoma

NCT06680245

Phase 1/2Recruiting

Study completion

NCT05688488

Q2 2027

Phase 2Recruiting

Non Muscle Invasive Bladder Cancer

NCT07646145

Q3 2027

Phase 1Not yet recruiting

Urothelial Carcinoma

NCT05979909

Q4 2027

Phase 2Recruiting

Effectiveness

NCT06388720

Clinical

Trials by Indication[1]

Bladder Cancer17 trials

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02311101·18 enrolled

Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer

Completed·MMedical Research Council·Phase 3·NCT00002490

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Terminated·BBioniche Life Sciences Inc.·Phase 3·NCT01200992·84 enrolled

Show 14 more trials

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00042887·58 enrolled

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00023842·97 enrolled

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

Recruiting·JJakob Kristian Jakobsen·Phase 4·NCT06781879·272 enrolled

Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT02070120·82 enrolled

A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00192049·90 enrolled

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Completed·MMark Dewhirst·Phase 1·NCT00734994·15 enrolled

Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Completed·UUniversity Hospital Birmingham·Phase 3·NCT00024349·350 enrolled

Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer

Unknown status·CCancer Research Campaign Clinical Trials Centre·Phase 3·NCT01094964·242 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04241185·520 enrolled

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00974818·50 enrolled

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02710734·78 enrolled

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Completed·VViralytics·Phase 1·NCT02316171·16 enrolled

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Completed·HHalozyme Therapeutics·Phase 1/2·NCT00318643·27 enrolled

GU-254: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Enfortumab Vedotin/Pembrolizumab for Bladder Cancer (RETAIN-3)

Recruiting·FFox Chase Cancer Center·Phase 2·NCT07908979·70 enrolled

Glaucoma7 trials

The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device

Completed·—·Phase 2·NCT02016898·100 enrolled

Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans

Unknown status·GGuy's and St Thomas' NHS Foundation Trust·N/A·NCT02989207·60 enrolled

Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma

Completed·AAthens Vision Eye Institute·Phase 2/3·NCT02901236·40 enrolled

Show 4 more trials

Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery

Not yet recruiting·SSt. Joseph's Healthcare Hamilton·Phase 3·NCT06680245·144 enrolled

Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia

Withdrawn·UUniversity of California, San Francisco·N/A·NCT02744690

Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 1·NCT00893490

Ahmed Glaucoma Valve Surgery With Mitomycin-C

Completed·UUniversity of California, San Francisco·Phase 2·NCT02805257·119 enrolled

Non-Small Cell Lung Cancer5 trials

Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Unknown status·CCancer Research UK·Phase 3·NCT00004209

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00003159·600 enrolled

Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

Unknown status·TThe Christie NHS Foundation Trust·Phase 3·NCT00004887

Show 2 more trials

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 3·NCT00003240·1,800 enrolled

Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Unknown status·—·Phase 2·NCT00005825

Pancreatic Cancer5 trials

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01296763·18 enrolled

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276744·249 enrolled

Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer

Terminated·IIRCCS San Raffaele·Phase 2·NCT00967291·21 enrolled

Show 2 more trials

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00386399

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003018·54 enrolled

Radiation Therapy3 trials

Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00068744·88 enrolled

Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer

Completed·—·Phase 3·NCT00025090·600 enrolled

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003596·682 enrolled

60 more indications

Intraoperative3 trials

Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome

Completed·PPrince of Songkla University·Phase 2/3·NCT01263834·39 enrolled

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

Terminated·UUniversity of California, Los Angeles·Phase 4·NCT03875911·19 enrolled

Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C

Completed·IIndiana University School of Medicine·Phase 4·NCT00346489·70 enrolled

Peritoneal Carcinomatosis3 trials

HIPEC for Peritoneal Carcinomatosis

Completed·—·Phase 2·NCT02040142·51 enrolled

A Phase II Single Arm Study of Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis

Recruiting·MMohammad Haroon Asif Choudry·Phase 2·NCT07475286·22 enrolled

Phase 1 Single Center Study to Evaluate Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Single Agent Mitomycin C (MMC) in Peritoneal Carcinomatosis (PC) From Solid Gastrointestinal Malignancies (sGI-PC) in Palliative Setting

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT07487168·24 enrolled

Prospective3 trials

A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation

Unknown status·WWhitten Laser Eye·Phase 4·NCT03126877·40 enrolled

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

Terminated·KKey-Whitman Eye Center·Phase 4·NCT03101501·9 enrolled

A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin C

Unknown status·FFichte, Endl & Elmer Eyecare·Phase 4·NCT03242317·40 enrolled

Breast Cancer2 trials

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting·UUNICANCER·Phase 2·NCT02299999·1,460 enrolled

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Completed·UUniversity Hospital Birmingham·Phase 3·NCT00003893·2,250 enrolled

Urothelial Carcinoma2 trials

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Not yet recruiting·MMcMaster University·Phase 1·NCT05979909·40 enrolled

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Completed·UUniversity of Florida·Phase 2·NCT03658304·29 enrolled

Radiotherapy2 trials

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Completed·LLund University Hospital·Phase 1·NCT01621217·21 enrolled

Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03381352·27 enrolled

Colorectal Cancer2 trials

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

Terminated·—·Phase 3·NCT00023868

Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer

Terminated·UUNICANCER·Phase 2·NCT00005944

MPA2 trials

Comparison Between Topical Mitomycin C and Cyclosporine

Completed·EEgymedicalpedia·Phase 1·NCT05627947·57 enrolled

The Bladder Instillation Comparison Study

Completed·CCorewell Health West·Phase 3·NCT02695771·101 enrolled

Gastric Cancer2 trials

Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02092298·21 enrolled

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03092518·27 enrolled

Peritoneal Cancer2 trials

Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00006112

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00024271

Liver Cancer2 trials

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01011010·11 enrolled

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

Completed·—·Phase 1·NCT01042041·18 enrolled

Efficacy and Safety2 trials

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Terminated·SSamyang Biopharmaceuticals Corporation·Phase 3·NCT02982395·36 enrolled

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Recruiting·SShaogang Wang·Phase 3·NCT06696794·180 enrolled

Stricture2 trials

Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture

Unknown status·TTang-Du Hospital·N/A·NCT02287389·160 enrolled

Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT04037072

Non-Muscle Invasive Bladder Neoplasms2 trials

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06919965·220 enrolled

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06211764·272 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Completed·WWashington University School of Medicine·Phase 2·NCT02369458·48 enrolled

CLE1 trial

Decorin in Sub Scleral Trabeculectomy

Unknown status·—·Phase 1·NCT03924544·52 enrolled

Effectiveness1 trial

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Recruiting·NNational Cancer Center, Korea·Phase 2·NCT06388720·82 enrolled

Sclerosing Cholangitis1 trial

Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

Unknown status·—·Phase 2·NCT01688024·130 enrolled

Colon Cancer1 trial

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01167725·340 enrolled

Malignant Mesothelioma1 trial

Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

Unknown status·BBritish Thoracic Society·Phase 2·NCT00030459

Cervical Cancer1 trial

Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003209·700 enrolled

Hepatocellular Carcinoma1 trial

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn·AAlbert Koong·Phase 3·NCT01327521

Stomach Cancer1 trial

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201747·80 enrolled

Neoadjuvant1 trial

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

Completed·JJørgen Bjerggaard Jensen·Phase 4·NCT03348969·120 enrolled

Intraepithelial Neoplasia1 trial

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Completed·CCoordinación de Investigación en Salud, Mexico·Phase 4·NCT02199327·18 enrolled

Steroid1 trial

The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements

Unknown status·UUnited States Naval Medical Center, San Diego·Phase 2/3·NCT02030990·300 enrolled

Dermatitis1 trial

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01324141·6 enrolled

Pterygium1 trial

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT01115517·51 enrolled

Soft Tissue Sarcoma1 trial

Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery

Completed·MMayo Clinic·Phase 2·NCT00652860·39 enrolled

Anal Carcinoma1 trial

Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy

Unknown status·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02369939·118 enrolled

Advanced Cancer1 trial

Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus

Terminated·GGynecologic Oncology Group·Phase 2·NCT00002993·30 enrolled

Malignant Pleural Mesothelioma1 trial

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Completed·MMedical Research Council·Phase 3·NCT00075699·840 enrolled

Intestinal Cancer1 trial

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

Completed·UUniversity Hospital Tuebingen·Phase 1/2·NCT00289445

Recurrent or Refractory1 trial

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Unknown status·AAstex Pharmaceuticals, Inc.·Phase 3·NCT00005870

Cytoreductive Surgery1 trial

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Completed·HHoly Name Medical Center, Inc.··NCT03604653·10 enrolled

Intraperitoneal Chemotherapy1 trial

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

Unknown status·UUniversity of Kansas Medical Center·Phase 2·NCT03073694·100 enrolled

Patients With Advanced Solid Tumors1 trial

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003710·12 enrolled

NEC1 trial

Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae

Completed·—·Phase 2·NCT00966056·60 enrolled

Age1 trial

Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C

Completed·MMedical University of Lublin·Phase 2·NCT03506542·53 enrolled

Ascites1 trial

Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00265863·1 enrolled

Intensity-modulated Radiation Therapy1 trial

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00423293·63 enrolled

Chemotherapy1 trial

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Terminated·GGynecologic Oncology Group·Phase 2·NCT00033644

Treatment1 trial

Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)

Recruiting·UUniversity of Southampton·Phase 3·NCT06513065·176 enrolled

Oxaliplatin1 trial

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Completed·WWake Forest University Health Sciences·Phase 2·NCT01580410·136 enrolled

Leukemia1 trial

Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

Completed·—·Phase 1·NCT00003003·29 enrolled

Head and Neck Cancer1 trial

Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer

Completed·YYale University·Phase 3·NCT00002507

Children1 trial

Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children

Unknown status·FFederal University of São Paulo·N/A·NCT00551824·10 enrolled

Function1 trial

Function and Modulation of Fibulin-1 Assembly in Nucleus of Corneal Fibroblasts

Unknown status·FFar Eastern Memorial Hospital··NCT01808495·5 enrolled

Tumors1 trial

Chemoembolization for Lung Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04200417·10 enrolled

Urethral stricture1 trial

Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture

Completed·—·Phase 2/3·NCT06232005·50 enrolled

Toxicity1 trial

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Active, not recruiting·UUniversity of Cincinnati·Phase 2/3·NCT05902533·33 enrolled

Anal Cancer1 trial

Adaptive Radiation in Anal Cancer

Recruiting·—·N/A·NCT05838391·20 enrolled

Gastric Adenocarcinoma1 trial

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03330028·29 enrolled

Peritoneal Mesothelioma1 trial

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04847063·60 enrolled

Non Muscle Invasive Bladder Cancer1 trial

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Medium-high Risk Non-Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial

Recruiting·SShanxi Province Cancer Hospital·Phase 2·NCT07646145·50 enrolled

Urothelial Cancer1 trial

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

Recruiting· Astellas logo

Astellas·Phase 3·NCT07566156·390 enrolled

Carcinoma of the Anal Canal1 trial

A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal

Completed·MMassachusetts General Hospital·Phase 1·NCT01858025·25 enrolled

Urinary Bladder Neoplasms1 trial

Toripalimab With Sequential Intravesical Gemcitabine-Mitomycin C Versus Toripalimab Alone for the Treatment of BCG-Unresponsive/-Intolerant High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized, Multicenter, Phase 2 Study

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07189793·106 enrolled

Solid Tumor Cancer1 trial

GEMINI: Phase II Study Using Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

Recruiting·SSarcoma Oncology Research Center, LLC·Phase 2·NCT07671534·60 enrolled

Unspecified6 trials

Therapeutic Instillation of Mistletoe

Active, not recruiting·AAbnoba Gmbh·Phase 3·NCT02106572·548 enrolled

Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords

Recruiting·EEye & ENT Hospital of Fudan University·Phase 1/2·NCT05688488·100 enrolled

A Study of Mitomycin C, Irinotecan, and Cetuximab

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00271011·13 enrolled

Show 3 more trials

Mitomycin-c Application for PRK

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT01504282·90 enrolled

Primary Tube Versus Trabeculectomy Study

Completed·UUniversity of Miami·Phase 4·NCT00666237·242 enrolled

Study of Mitomycin-C Application in Laryngotracheal Stenosis

Terminated·UUniversity of California, San Francisco·N/A·NCT01523275·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 119 trial records for Mitomycin c. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitomycin c compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitomycin c. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

Mitomycin c

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Bladder Cancer17 trials

Glaucoma7 trials

Non-Small Cell Lung Cancer5 trials

Pancreatic Cancer5 trials

Radiation Therapy3 trials

Intraoperative3 trials

Peritoneal Carcinomatosis3 trials

Prospective3 trials

Breast Cancer2 trials

Urothelial Carcinoma2 trials

Radiotherapy2 trials

Colorectal Cancer2 trials

MPA2 trials

Gastric Cancer2 trials

Peritoneal Cancer2 trials

Liver Cancer2 trials

Efficacy and Safety2 trials

Stricture2 trials

Non-Muscle Invasive Bladder Neoplasms2 trials

Head and Neck Squamous Cell Carcinoma1 trial

CLE1 trial

Effectiveness1 trial

Sclerosing Cholangitis1 trial

Colon Cancer1 trial

Malignant Mesothelioma1 trial

Cervical Cancer1 trial

Hepatocellular Carcinoma1 trial

Stomach Cancer1 trial

Neoadjuvant1 trial

Intraepithelial Neoplasia1 trial

Steroid1 trial

Dermatitis1 trial

Pterygium1 trial

Soft Tissue Sarcoma1 trial

Anal Carcinoma1 trial

Advanced Cancer1 trial

Malignant Pleural Mesothelioma1 trial

Intestinal Cancer1 trial

Recurrent or Refractory1 trial

Cytoreductive Surgery1 trial

Intraperitoneal Chemotherapy1 trial

Patients With Advanced Solid Tumors1 trial

NEC1 trial

Age1 trial

Ascites1 trial

Intensity-modulated Radiation Therapy1 trial

Chemotherapy1 trial

Treatment1 trial

Oxaliplatin1 trial

Leukemia1 trial

Head and Neck Cancer1 trial

Children1 trial

Function1 trial

Tumors1 trial

Urethral stricture1 trial

Toxicity1 trial

Anal Cancer1 trial

Gastric Adenocarcinoma1 trial

Peritoneal Mesothelioma1 trial

Non Muscle Invasive Bladder Cancer1 trial

Urothelial Cancer1 trial

Carcinoma of the Anal Canal1 trial

Urinary Bladder Neoplasms1 trial

Solid Tumor Cancer1 trial

Unspecified6 trials

References

Drug Info

Quick Facts

Related News